Dr. Rafael Fonseca, an expert in multiple myeloma treatment, discusses the future of MM treatment, the debate between CAR-T therapies and bispecifics, the role of measurable residual disease (MRD), the potential for bispecific therapies to democratize access to advanced treatments, and the paradigm shift toward prioritizing deeper responses, including MRD negativity, for long-term cure in myeloma patients.

Gareth Morgan, Rafael Fonseca, Leif Bergsagel, and Keith Stewart discuss highlights from day two of the Myeloma 2022 meeting, covering topics such as BCL2 inhibitors, T-cell exhaustion, immunotherapy, targeted therapies, combination therapies, minimal residual disease, and the efficacy of Carti therapy in managing melon.